ABPI statement on biomarker testing

The ABPI commented in support of a call led by the Institute of Cancer Research (ICR) for all cancer patients to be offered genetic testing so they can get the best treatments available for them.  

Biomarker tests provide crucial information to help doctors select the treatments that will have the best chance of success in each person. Dr Jennifer Harris, ABPI Director of Research Policy

Dr Jennifer Harris, Director of Research policy at the ABPI said:  

“All patients, including cancer patients, should be able to get the best treatments available for their condition.

“Biomarker tests provide crucial information to help doctors select the treatments that will have the best chance of success in each person.

“Overcoming the barriers to developing and using biomarker tests would be a big step forward for personalised care. We will continue to work with the ICR and other partners to help make this happen.”

TAGS
  • Cancer

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.